Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that Dapagliflozin, as a highly selective SGLT-2 inhibitor,38 may have the ability to influence the function of central autonomic control that results in neural activation related to BP and HR regulation.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [38]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Kidney: Physiology and Pathophysiology
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-544_3 · Cited by 1,673
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Research works printed but not linked: 17
- Washburn W., 2007, 234th National ACS Meeting
- 2006, Diabetes Atlas
- Bertoni A. G., 2007, Diabetes Care
- Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199
- Moe O. W., 2000, The Kidney, 375
- Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229
- Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201
- Wells R. G., 1992, Am. J. Physiol., 263, F459
- Santer R., 2000, J. Inher. Metab. Dis., 23, 178
- 2004, Chem. Abstr., 142, 94061
- 2004, Chem. Abstr., 141, 332411
- 2004, Chem. Abstr., 141, 123854
- 2003, Chem. Abstr., 138, 153771
- 2001, Chem. Abstr., 135, 273164
- 2001, Chem. Abstr., 135, 273163
- 2003, Chem. Abstr., 138, 221784
- 2004, Chem. Abstr., 141, 89317
Cited by
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
“Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM 2011 Glucose transport by human renal Na /D-glucose cotransporters SGLT1 and SGLT2.”
BackgroundInfluentialNatural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860
SGLT2 inhibition — a novel strategy for diabetes treatment
Chao, E. C., & Henry, R. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3180 · Cited by 822
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
“Dapagliflozin is the first in a new class of oral selective sodium-glucose cotransporter 2 (SGLT2) inhibitors designed for treating type 2 diabetes (8,9).”
BackgroundRecent Advances in the Chemical Synthesis of C-Glycosides
Yang, Y., & Yu, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00234 · Cited by 664
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Hyperglycemia Promotes Myelopoiesis and Impairs the Resolution of Atherosclerosis
Nagareddy, P. R., Murphy, A. J., Stirzaker, R. A., Hu, Y., Yu, S., Miller, R. G., Ramkhelawon, B., Distel, E., Westerterp, M., Huang, L.-S., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.001 · Cited by 577
“Normoglycemia attenuated the expansion and proliferation of CMP and GMPs in both STZand Akita diabetic mice, an effect that was reproduced with a different SGLT2i, dapagliflozin (Meng et al., 2008) (Figure S3).”
BackgroundPetrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA · doi:10.1001/jama.2020.1906 · Cited by 531
Nauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
“class of glucose-lowering medications, the selective sodium-glucose cotransporter 2 (SGLT2) inhibitors (9).”
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493
Bolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 482
“Dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), increases urinary glucose excretion by reducing renal glucose reabsorption [5] and improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) when used as monotherapy [6] or when added to metformin [7,8], sitagliptin [9], glimepiri…”
BackgroundWilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
“Dapagliflozin, a competitive and highly selective inhibitor of sodium–glucose cotransporter 2 (10, 11), reduces renal glucose reabsorption, increases renal glucose excretion, and reduces hyperglycemia in a dose-dependent manner (12).”
BackgroundSGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., & Whaley, J. M. (2008) · Diabetes · doi:10.2337/db07-1472 · Cited by 421
“Dapagliflozin was synthesized by Bristol-Myers Squibb Discovery Chemistry (23).”
MethodSelf-citationRosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 408
“Dapagliflozin, an SGLT2 inhibitor (4), has been shown to improve glycemic control in patients with type 2 diabetes as monotherapy (5) and in combinationwithmetformin (6), sulfonylurea (7), or insulin (8), but not yet with a thiazolidinedione.”
BackgroundStrojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
“One such mechanism targets the sodium-glucose cotransporter 2 (SGLT2), located principally in the proximal tubule of the kidney nephron, which reabsorbs the majority of glucose filtered by the glomerulus [6].”
BackgroundInfluentialPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
“This led to development of the synthetic analogs canagliflozin (4), dapagliflozin (5), and empagliflozin (6) (Fig.”
BackgroundKomoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396
Nomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., Yamamoto, Y., Ueta, K., Kimata, H., Nakayama, K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100332n · Cited by 385
Current anti-diabetic agents and their molecular targets: A review
Kerru, N., Singh-Pillay, A., Awolade, P., & Singh, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.061 · Cited by 369
Renal reabsorption in 3D vascularized proximal tubule models
Lin, N. Y. C., Homan, K. A., Robinson, S. S., Kolesky, D. B., Duarte, N., Moisan, A., & Lewis, J. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815208116 · Cited by 358
Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009) · Kidney International · doi:10.1038/ki.2009.87 · Cited by 358
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.251 · Cited by 350
SGLT inhibitors in management of diabetes
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 332
The modification of natural products for medical use
Guo, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.06.003 · Cited by 328
Thiadiazole—a Promising Structure in Medicinal Chemistry
Li, Y., Geng, J., Liu, Y., Yu, S., & Zhao, G. (2013) · ChemMedChem · doi:10.1002/cmdc.201200355 · Cited by 303
Bokor, É., Kun, S., Goyard, D., Tóth, M., Praly, J.-P., Vidal, S., & Somsák, L. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00475 · Cited by 304
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
“The third agent of this class was Empa, which has the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold) among the commercially available SGLT2i [21].”
BackgroundInfluentialGlucose transport families SLC5 and SLC50
Wright, E. M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.11.002 · Cited by 301
“, 2011) and two, dapagliflozin (Meng et al., 2008) and canagliflozin (Nomura et al.”
BackgroundInfluentialWilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & for the Dapagliflozin 006 Study Group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 291
“Keywords: glycaemic control, insulin, randomized trial, renal glucose handling, SGLT2 inhibitor, type 2 diabetes Date submitted 16 May 2013; date of first decision 21 June 2013; date of final acceptance 18 July 2013”
BackgroundInfluentialThe structural modification of natural products for novel drug discovery
Yao, H., Liu, J., Xu, S., Zhu, Z., & Xu, J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1272757 · Cited by 275
“Later, substitution of the O-glycoside with the C-glycoside avoided hydrolysis by β-glucosidases, and with some additional modifications on phenyl groups, the second-generation analogues including dapagliflozin (66) and canagliflozin (67) resulted, both of which were approved in Europe in 2012 and the US in 2013 [80,8…”
BackgroundKasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0104-3 · Cited by 276
“In vitro studies with recombinant cytochrome (CYP) isoforms indicate that the metabolism of dapagliflozin may be catalyzed by several CYP enzymes, including CYP1A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, and CYP3A4 [10].”
BackgroundInfluentialGlucose transport by human renal Na + / d -glucose cotransporters SGLT1 and SGLT2
Hummel, C. S., Lu, C., Loo, D. D. F., Hirayama, B. A., Voss, A. A., & Wright, E. M. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00388.2010 · Cited by 270
“Such inhibitors completely block hSGLT2 activity in vitro (12, 17) but a maximum of 50% of glucose reabsorption in vivo (13).”
BackgroundMethodCarbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Nair, S., & Wilding, J. P. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0473 · Cited by 263
“0 h in rats, dogs, and monkeys, respectively (45).”
BackgroundDapagliflozin: A Review in Type 2 Diabetes
Dhillon, S. (2019) · Drugs · doi:10.1007/s40265-019-01148-3 · Cited by 243
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Bailey, C. J., Day, C., & Bellary, S. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01442-z · Cited by 248
“SGLT1 is most abundant in the apical membranes of enterocytes where it mediates glucose uptake from the intestinal lumen.”
BackgroundInfluentialIndustrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Weber, M. A., Mansfield, T. A., Cain, V. A., Iqbal, N., Parikh, S., & Ptaszynska, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00417-9 · Cited by 254
Latva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253
“The effect of this class of drugs is based on suppressing renal glucose reabsorption and increasing excretion of glucose to urine, resulting in improved glycemic control independent of insulin actions, as well as reduced body weight (1,2).”
BackgroundAnti-diabetic drugs recent approaches and advancements
Dowarah, J., & Singh, V. P. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115263 · Cited by 227
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
Del Prato, S., Nauck, M., Durán‐Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., & Parikh, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12459 · Cited by 233
“SGLT2 inhibitors act by reducing renal glucose reabsorption from the proximal tubule, promoting excretion of excess glucose, net calorie loss, and improved glycaemic control [6,8,9].”
BackgroundRenal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217
Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01630.x · Cited by 215
“Keywords: body composition, clinical trial, renal glucose handling, SGLT2 inhibitor, type 2 diabetes Date submitted 13 February 2012; date of first decision 12 March 2012; date of final acceptance 7 May 2012”
BackgroundInfluentialGlucose Control by the Kidney: An Emerging Target in Diabetes
Marsenic, O. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.031 · Cited by 217
“However, several major T ission from Meng et al, © 2008 American Chemical ociety. imitations make phlorizin unsuitable for theraeutic use.”
BackgroundDevenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212
“Dapagliflozin is a potent and selective SGLT2 inhibitor (16) which has been shown to induce glucose excretion by 20–85 g/day in humans (17–19) and 0.”
BackgroundVulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S. J., & List, J. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.012 · Cited by 213
Urinary tract infections in patients with diabetes treated with dapagliflozin
Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S. J., & List, J. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.05.004 · Cited by 205
Koepsell, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.017 · Cited by 187
Obermeier, M., Yao, M., Khanna, A., Koplowitz, B., Zhu, M., Li, W., Komoroski, B., Kasichayanula, S., Discenza, L., Washburn, W., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029165 · Cited by 183
“In summary, dapagliflozin is a potent inhibitor of SGLT2 and shows a reduction in plasma glucose in animal models (Han et al., 2008; Meng et al., 2008).”
BackgroundSelf-citationGlucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
List, J. F., & Whaley, J. M. (2011) · Kidney International · doi:10.1038/ki.2010.512 · Cited by 184
Self-citationAbdul-Ghani, M. A., & DeFronzo, R. A. (2008) · Endocrine Practice · doi:10.4158/ep.14.6.782 · Cited by 184
Sodium–glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drug
Idris, I., & Donnelly, R. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00982.x · Cited by 181
Ohtake, Y., Sato, T., Kobayashi, T., Nishimoto, M., Taka, N., Takano, K., Yamamoto, K., Ohmori, M., Yamaguchi, M., Takami, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300884k · Cited by 174
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.-D., Kyrou, I., Efstathopoulos, E., Randeva, H. S., & Kassi, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 165
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01659.x · Cited by 167
Cascade Reactions: A Driving Force in Akuammiline Alkaloid Total Synthesis
Smith, J. M., Moreno, J., Boal, B. W., & Garg, N. K. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201406866 · Cited by 168
Zhu, F., Rourke, M. J., Yang, T., Rodriguez, J., & Walczak, M. A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b07891 · Cited by 165
Kakinuma, H., Oi, T., Hashimoto-Tsuchiya, Y., Arai, M., Kawakita, Y., Fukasawa, Y., Iida, I., Hagima, N., Takeuchi, H., Chino, Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901893x · Cited by 159
Washburn, W. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8013019 · Cited by 160
Self-citationSuzuki, M., Honda, K., Fukazawa, M., Ozawa, K., Hagita, H., Kawai, T., Takeda, M., Yata, T., Kawai, M., Fukuzawa, T., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191593 · Cited by 158
Zhu, F., Rodriguez, J., Yang, T., Kevlishvili, I., Miller, E. M., Yi, D., O’Neill, S., Rourke, M. J., Liu, P., & Walczak, M. A. A. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08707 · Cited by 158
Sharma, M., Pandey, S., Chauhan, K., Sharma, D., Kumar, B. N., & Chauhan, P. M. S. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo2020856 · Cited by 156
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Neumiller, J. J., White, J. R., & Campbell, R. K. (2010) · Drugs · doi:10.2165/11318680-000000000-00000 · Cited by 170
“Of additional benefit, SGLT2 inhibitor therapy is expected to be associated with a low risk of hypoglycaemia because there is no interference with the normal counter-regulatory mechanisms of glucose homeostasis.([49]) Mechanistically, SGLT2 inhibitors could be used as monotherapy or as a component of combination thera…”
BackgroundBailey, C. J., Villegas, E. C. M., Woo, V. C., Tang, W., Ptaszynska, A., & List, J. F. (2014) · Diabetic Medicine · doi:10.1111/dme.12624 · Cited by 158
Škrtić, M., & Cherney, D. Z. I. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 163
“dapagliflozin [30], canagliflozin [31] and others [32].”
Modular and Stereoselective Synthesis of C-Aryl Glycosides via Catellani Reaction
Lv, W., Chen, Y., Wen, S., Ba, D., & Cheng, G. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07634 · Cited by 147
Gaspari, T. A., Spizzo, I., Liu, H., Hu, Y., Simpson, R. W., Widdop, R. E., & Dear, A. E. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117733626 · Cited by 156
Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R., & Griffen, S. C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007046 · Cited by 139
“It is approved for the treatment of type 2 diabetes mellitus (T2DM), where it promotes glycosuria.(1,5) T2DM increases the incidence of congestive heart failure (CHF).”
BackgroundInsights into drug discovery from natural products through structural modification
Chen, J., Li, W., Yao, H., & Xu, J. (2015) · Fitoterapia · doi:10.1016/j.fitote.2015.04.012 · Cited by 152
Mascitti, V., Maurer, T. S., Robinson, R. P., Bian, J., Boustany, C., Brandt, T. A., Collman, B. M., Kalgutkar, A. S. S., Klenotic, M. K., Leininger, M. T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200049r · Cited by 138
Kurosaki, E., & Ogasawara, H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.003 · Cited by 148
Glycomimetics for the inhibition and modulation of lectins
Leusmann, S., Ménová, P., Shanina, E., Titz, A., & Rademacher, C. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00954d · Cited by 141
Choi, C. (2016) · Molecules · doi:10.3390/molecules21091136 · Cited by 146
“[43] developed dapagliflozin, with lipophilic thoxy substituents at the 4-position on the B-ring of phlorizin (Figure 1).”
BackgroundInfluentialStereoselective C-Glycosylation Reactions with Arylzinc Reagents
Lemaire, S., Houpis, I. N., Xiao, T., Li, J., Digard, E., Gozlan, C., Liu, R., Gavryushin, A. E., Diène, C. R., Wang, Y., et al. (2012) · Organic Letters · doi:10.1021/ol300220p · Cited by 132
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 129
Kasichayanula, S., Liu, X., Benito, M. P., Yao, M., Pfister, M., LaCreta, F. P., Humphreys, W. G., & Boulton, D. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12056 · Cited by 121
Self-citationKasichayanula, S., Chang, M., Hasegawa, M., Liu, X., Yamahira, N., LaCreta, F. P., Imai, Y., & Boulton, D. W. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01359.x · Cited by 117
“The renal SGLT type 2 (SGLT2) accounts for the majority of glucose reabsorption in the kidney [6] and an orally active, potent and selective inhibitor of SGLT2—dapagliflozin—is under development for the treatment of T2DM [7,8].”
BackgroundDevineni, D., & Polidori, D. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0285-z · Cited by 125
“The corresponding selectivity ratio was approximately 1200 for dapagliflozin [9] and approximately 2600 for empagliflozin [10].”
BackgroundNauck, M. A., Prato, S. D., Durán-Garcia, S., Rohwedder, K., Langkilde, A. M., Sugg, J. E., & Parikh, S. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12327 · Cited by 114
“As has been noted with the SGLT2-inhibitor class [15,17,31–38], events suggestive of genital infections and of UTIs, which included non-specific symptoms as well as clinically diagnosed infections, were more frequent with dapagliflozin compared with glipizide and were more commonly reported in women.”
BackgroundAccess to the Akuammiline Family of Alkaloids: Total Synthesis of (+)-Scholarisine A
Adams, G. L., Carroll, P. J., & Smith, A. B. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3111626 · Cited by 114
Wang, X., Zhang, L., Byrne, D. P., Nummy, L. J., Weber, D., Krishnamurthy, D., Yee, N. K., & Senanayake, C. H. (2014) · Organic Letters · doi:10.1021/ol501755h · Cited by 113
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0713-z · Cited by 112
Total Synthesis of (+)-Scholarisine A
Adams, G. L., Carroll, P. J., & Smith, A. B. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211840k · Cited by 109
Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Meneses, M. J., Silva, B. M., Sousa, M., Sá, R., Oliveira, P. F., & Alves, M. G. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710145753 · Cited by 132
“In addition, it has 1200-fold selectivity for SGLT2 over SGLT1 [148].”
BackgroundGiaccari, A., Sorice, G. P., & Muscogiuri, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.018 · Cited by 121
“In animal models remogliflozin [128] exhibited efficacy; this data was confirmed by short-term studies with dapagliflozin [129] (12 weeks) and sergliflozin [130] (2 weeks) in patients.”
Abbas, G., Al‐Harrasi, A., Hussain, H., Hamaed, A., & Supuran, C. T. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.02.009 · Cited by 107
Dearomative logic in natural product total synthesis
Huck, C. J., Boyko, Y. D., & Šarlah, D. (2022) · Natural Product Reports · doi:10.1039/d2np00042c · Cited by 102
SGLT2 inhibitors: molecular design and potential differences in effect
Isaji, M. (2011) · Kidney International · doi:10.1038/ki.2010.511 · Cited by 112
“12 and 1391 nmol/l toward human SGLT2 and human SGLT1, respectively) than remogliflozin and is a representative compound of SGLT2 inhibitors with a C-glycoside structure, which is a recent major category of SGLT2 inhibitors, and the first runner of SGLT2 development for clinical use.(22,45) These C-arylglycosides are…”
BackgroundWei, R., Cui, X., Feng, J. B., Gu, L., Lang, S., Wei, T., Yang, J., Liu, J., Le, Y., Wang, H., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154324 · Cited by 103
Metadata
- Authors
- Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., Zahler, R., Deshpande, P. P., Pullockaran, A., Hagan, D. L., Morgan, N., Taylor, J. R., Obermeier, M. T., Humphreys, W. G., Khanna, A., Discenza, L., Robertson, J. G., Wang, A., Han, S., Wetterau, J. R., Janovitz, E. B., Flint, O. P., Whaley, J. M., & Washburn, W. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Metabolic Diseases Chemistry, Process R & D, Metabolic Diseases Biology, Pharmacological Candidate Optimization, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543
- Corresponding author
- Meng, Wei
- Washburn, William N.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 5
- Pages
- 1145-1149
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2026609170
- Cited by
- 634
- References
- 39
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 28 · 2023: 23 · 2022: 35 · 2021: 32 · 2020: 40 · 2019: 34 · 2018: 26 · 2017: 22 · 2016: 35 · 2015: 44 · 2014: 40 · 2013: 36 · 2012: 43
- FWCI
- 35.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, antidiabetic drug discovery, blood glucose reduction, streptozotocin-induced hyperglycemia, ADME properties
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Humans, Hypoglycemic Agents, Kidney, Stereoisomerism, Sodium-Glucose Transporter 2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.